Aspen Neurosciences is developing a cell therapy that uses a patient’s own stem cells to develop a personalized treatment for Parkinson’s disease. The approach is slightly different than that of Bayer, whose experimental Parkinson’s cell therapy is made from stem cells sourced from healthy donors.
Numerous companies with remote-monitoring and telehealth services closed funding rounds this week. Tyto Care, which gives users the tools to conduct an at-home medical exam with their doctor, raised $50 million. On the biotech side, Aspen Neuroscience, which is developing a new treatment for Parkinson's disease, raised $70 million.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.